Sign In
to Vote &
Create Storyboards.
 
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent increase in mutations detected in cancer predisposition genes in patients with a prior history of colon cancer and/or polyps. Myriad is presenting this clinical study at the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA) Annual Meeting in Anaheim, Calif. Patients with a family history of colon cancer...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard